CompletedNCT03116191Updated Apr 13, 2018

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

A Phase 2 interventional study of SK-1404 and Placebo in Nocturia Due to Nocturnal Polyuria, sponsored by Sanwa Kagaku Kenkyusho Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 55 Years to 79 Years. Per ClinicalTrials.gov, last updated 2018-04-13.

Sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. · Phase 2, Interventional, and Treatment

Phase: Phase 2
Study type: Interventional
Enrollment: 125
Allocation: Randomized
Ages: 55 Years to 79 Years
Sex: All

Study summary

The purpose of this trial is to demonstrate efficacy of SK-1404 against placebo for the treatment of subjects with nocturia due to nocturnal polyuria, during 4 weeks of treatment.

Conditions studied

Nocturia Due to Nocturnal Polyuria

Browse trials for

In context

Nocturia

134 studies on the registry are indexed under Nocturia; 22 are open to participants now.

This study's enrollment of 125 is above the median of 71 across 108 interventional studies indexed under Nocturia.

Browse Nocturia studies →

Lead sponsor

Sanwa Kagaku Kenkyusho Co., Ltd. is the lead sponsor of 19 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 55 Years to 79 Years
Sexes eligible: All
Accepts healthy volunteers: No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

5 > nocturnal voids ≥2
NPI >0.33

Exclusion criteria

Exclusion Criteria:

Polydipsia
Cardiac failure
Syndrome of inappropriate antidiuretic hormone secretion
Hyponatraemia
Uncontrolled diabetes mellitus
Uncontrolled hypertension
Moderate or severe over-active bladder (OAB)
Severe benign prostate hyperplasia (BPH)
Sleep apnoea
Interstitial cystitis
Stress urinary incontinence
Diabetes insipidus
Complication or a history of urological cancer

Study design

Phase: Phase 2
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Double (Participant, Investigator)
Enrollment: 125 participants (actual)

Study arms

Experimental
SK-1404 high dose
Drug: SK-1404
Experimental
SK-1404 middle dose
Drug: SK-1404
Experimental
SK-1404 low dose
Drug: SK-1404
Placebo comparator
Placebo
Drug: Placebo

Interventions

DrugSK-1404
4 weeks of repeated administration of SK-1404 to the patients of nocturia
DrugPlacebo
4 weeks of repeated administration of Placebo to the patients of nocturia

What researchers measure

Primary outcomes

Change from baseline in mean number of nocturnal voids
Assessed by the voiding diary
Time frame: 4 weeks

Secondary outcomes

Change from base line in mean nocturnal urine volume
Assessed by the voiding diary
Time frame: 4 weeks
Change from base line in mean time to first awakening to void
Assessed by the voiding diary
Time frame: 4 weeks
Change from base line in mean Nocturnal Polyuria Index (NPI)
Assessed by the voiding diary
Time frame: 4 weeks
Change from base line in the score of Nocturia-Specific Quality-of-Life Questionnaire (N-QoL)
Assessed by the voiding diary
Time frame: 4 weeks

Study locations

1 site

Investigational site (there may be other sites in this country)
Tokyo, Japan

Timeline

Tracking since Sep 25, 2026

ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Dec 2017, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered: Apr 6, 2017
First posted: Apr 14, 2017
StartActual: Feb 23, 2017
Primary completionActual: Dec 15, 2017
CompletionActual: Dec 15, 2017
Last update: Apr 13, 2018

What these dates mean

Start.: When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.: When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.: When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.: Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.

No changes since tracking began. The registry record was last updated on Apr 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT03116191
Lead sponsor: Sanwa Kagaku Kenkyusho Co., Ltd.
Responsible party: Sponsor
First posted: Apr 14, 2017
Start date: Feb 23, 2017
Primary completion: Dec 15, 2017
Completion: Dec 15, 2017
Last update: Apr 13, 2018

Oversight

FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Nocturia →

Other studies from this sponsor

Sanwa Kagaku Kenkyusho Co., Ltd.

Start the discussion